Jackée Harry says 50-pound loss from a GLP-1 led to a facelift to address a sagging neck

Jackée Harry told PEOPLE she lost 50 pounds after taking a GLP-1 medication prescribed for pre-diabetes and later underwent a facelift to treat a sagging neck; she is recovering and says she is no longer taking the medication.

Jackée Harry described a recent health- and appearance-related journey that began during the COVID-19 pandemic when she was diagnosed with pre-diabetes and was prescribed a GLP-1 medication. She reported common side effects early in treatment and said the medication coincided with substantial weight loss. After losing about 50 pounds over roughly a year and a half, she became concerned about a sagging neck and chin and decided to have a facelift. The surgery was performed on September 30, 2025, and she is currently recovering while reporting improved health markers. Key points: - Jackée Harry was prescribed a GLP-1 medication for pre-diabetes and reported side effects such as dizziness, nausea and constipation during early use. - She said the treatment was followed by weight loss of about 50 pounds over roughly 18 months and that her endocrinologist reported she is no longer pre-diabetic. - Dr. Patrick Davis, a facial plastic surgeon, described the facial changes as consistent with rapid or dramatic weight loss, a pattern the article referenced as "Ozempic face." - Harry underwent a facelift on September 30, 2025, to address looseness in her neck and chin that she noticed after the weight loss. - She is still recovering, reports some pain and swelling, and said swelling should continue to improve over the next several months. - Harry told PEOPLE she is not currently taking the GLP-1 medication and does not have immediate plans to resume it for weight loss, though she continues to speak with her doctor. Summary: Harry reports medical treatment for pre-diabetes that coincided with substantial weight loss and then elective facial surgery to address resulting changes in her neck and chin. She is recovering from the facelift, says her health markers have improved, and has decided to pause the GLP-1 treatment for now; further follow-up with medical providers was described but long-term plans were not specified.